Australia markets closed

ALLK Sep 2022 15.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.2000+0.0500 (+33.33%)
At close: 01:36PM EDT
Full screen
Previous close0.1500
Open0.2000
Bid0.0500
Ask0.2500
Strike15.00
Expiry date2022-09-16
Day's range0.2000 - 0.2000
Contract rangeN/A
Volume1
Open interest1.02k
  • GlobeNewswire

    Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

    SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2022. Recent Allakos Events Submitted End-of-Phase 2 briefing package to FDA to discuss Phase 2 KRYPTOS data and development pathway of lirentelimab in patients with eosinophil

  • GlobeNewswire

    Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

    SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. “We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expert

  • Simply Wall St.

    Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...